NCT03380520View on ClinicalTrials.gov

Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

December 31, 2020

Study Completion Date

August 4, 2021

Conditions
Heart Failure
Interventions
DRUG

Ferric Carboxymaltose

Ferric carboxymaltose will be administered according to product specification dosing

DRUG

Placebo

IV nacl 0.9%

Trial Locations (1)

3500

Pieter Martens, Genk

All Listed Sponsors
collaborator

Ziekenhuis Oost-Limburg

OTHER

lead

Hasselt University

OTHER

NCT03380520 - Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy | Biotech Hunter | Biotech Hunter